The RUNX2 pathway is highly active in late-stage CAVD as it triggers the transition of valve cells (mainly VICs, but also transdifferentiated VECs) into an osteoblastic phenotype [39]. This evidence concerns the gene RUNX2 and congenital bilateral aplasia of vas deferens from CFTR mutation.